Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to represent a notable step forward for body treatment. Preliminary clinical tests have demonstrated substantial decreases in visceral mass , potentially outperforming current obesity therapies . However